Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 14.16$. Average daily volumn in 3 months 2.7M. Market cap 43.43B



Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 13.98$. Total volume : 240.65k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price
13.98$
Change
-0.06
Volume
240.65k

Previous Close14.04
Open13.92
Day Range13.91-14.00
Bid13.95 x 800
Ask13.96 x 2.9k
Volume240.65k
Average Volume2.7M
Market Cap43.43B
Beta0.90
52 Week Range13.05-17.31
Trailing P/E25.90
Foward P/E7.06
Dividend (Yield %)5.72%
Ex-Dividend Date2021-09-29



Financial Details


According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2022 were 3.57T an increase(0%) over the years 2021 revenue that were of 3.2T. In 2022 the company's total earnings were 230.06B while total earnings in 2021 were 376B(-38.83%).


Loading ...



Organization

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynov... ate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Market Cap:
43.43B
Revenue:
3.57T
Total Assets:
13.18T
Total Cash:
849.7B


News about "Takeda Pharmaceutical Company Limited"

takeda-pharmaceutical-company-limited-nysetak-stake-reduced-by-manning-napier-group-llc-image

Takeda Pharmaceutical Company Limited (NYSE:TAK) Stake Reduced by Manning & Napier Group LLC

Source from : Defense World - 10 hours ago

Manning & Napier Group LLC cut its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK โ€“ Get Rating) by 8.7% during the 1st quarter, Holdings Channel.com reports. The fund owned 291,402 shares ...See details»


The Behavior Of Takeda Pharmaceutical Company Limited (TAK) Stock Is Not As Predictable As You Think

Source from : stocksregister - 1 days ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) at last check was buoying at $13.91 on Thursday, June 30, with a rise of 0.47% from its closing price on previous day. Taking a look at stock we notice ...See details»


Meeting and exceeding analyst predictions: Takeda Pharmaceutical Company Limited (TAK)

Source from : investchronicle - 1 days ago

At the end of the latest market close, Takeda Pharmaceutical Company Limited (TAK) was valued at $13.85. In that particular session, Stock kicked-off at the price of $13.83 while reaching the peak ...See details»


caprock-group-inc-has-264000-holdings-in-takeda-pharmaceutical-company-limited-nysetak-image

CAPROCK Group Inc. Has $264,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Source from : Defense World - 5 days ago

CAPROCK Group Inc. lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK โ€“ Get Rating) by 21.1% in the 1st quarter, according to the company in its most recent 13F filing with ...See details»


Takeda Pharmaceutical Co. Ltd.

Source from : Wall Street Journal - 9 days ago

1 Day TKPHF 3.45% DJIA 2.53% S&P 500 2.86% Health Care/Life Sciences -0.66% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...See details»


Takeda Pharmaceutical Co Ltd - Stock Quote TKPHF

Source from : Morningstar%2c Inc. - 4 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


27,504 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Acquired by Veriti Management LLC

Source from : ETF Daily News - 6 days ago

Takeda Pharmaceutical stock opened at $13.84 on Friday. The companyโ€™s fifty day simple moving average is $14.18 and its 200-day simple moving average is $14.40. The company has a quick ratio of ...See details»


Takeda Pharmaceutical Company Limited (TKD.F)

Source from : Yahoo Finance - 9 days ago

but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda. As the Bank of Japan reiterated its commitment to loose monetary policy on Friday, affirming ...See details»


Takeda leases future Kendall Square building

Source from : The Business Journals - 9 days ago

Takeda Pharmaceutical Company Ltd. has agreed to lease a 16-story Kendall Square lab-and-office building under development from BioMed Realty, part of an effort to consolidate more of its ...See details»


Bypassing U.S., Takeda takes its dengue shot to the tropics

Source from : ๆœๆ—ฅๆ–ฐ่ž็คพ - 7 days ago

Takeda Pharmaceutical Co., Ltd., plans to seek approval for the experimental ... whose rigorous reviews are often used as a benchmark worldwide, company executives told Reuters.See details»


takeda-is-now-in-a-good-phase-for-growth-ceo-weber-says-image

Takeda Is โ€˜Now In a Good Phaseโ€™ for Growth, CEO Weber Says

Source from : Yahoo News UK - 2 days ago

Takeda Pharmaceutical Co.โ€™s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change ...See details»


japanese-drug-giant-takeda-will-move-into-16-story-building-planned-for-kendall-square-image

Japanese drug giant Takeda will move into 16-story building planned for Kendall Square

Source from : The Boston Globe on MSN.com - 8 days ago

The company says it wants to create a consolidated campus in Cambridge and is signing a 15-year lease on a planned 600,000 square-foot lab and office space at 585 Third St.See details»


Takeda Pharmaceutical Company Limited (TAK)

Source from : Yahoo Finance - 4 days ago

but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda. As the Bank of Japan reiterated its commitment to loose monetary policy on Friday, affirming its ...See details»


Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Source from : Stockhouse - 4 days ago

For the purposes of this notice, โ€œpress release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or ...See details»